Companies
Multi-plant target accounts across all verticals.
Abbott Laboratories
pharmaAbbott Laboratories, a diversified healthcare giant with 30+ US manufacturing locations, recently received FDA clearance for its next-generation Ultreon 3.0 AI-powered coronary imaging platform, demonstrating continued innovation in medical devices. The company maintains strong investor interest as a Dividend King with 54 consecutive years of dividend increases and a yield approaching 3%, though recent portfolio moves show some institutional reallocation away from the stock.
Baxter International
pharmaBaxter beat Q1 2026 earnings and revenue estimates despite margin contraction and lower year-over-year profits, driven by strong demand in medical devices and therapies. The company is focused on business stabilization and operational improvement across its diversified manufacturing footprint.
Becton Dickinson
pharmaBD is leveraging AI-powered medication management systems and launching breakthrough vascular access technology (CentroVena One™) to strengthen its market position in medical devices. The company maintains a robust North American manufacturing footprint with 20+ plants while facing near-term earnings pressure from China dynamics and research funding headwinds.
Cardinal Health
pharmaCardinal Health raised its 2026 profit forecast for the second time this year, driven by strong demand for specialty drugs and pharma growth despite a revenue miss in Q3. The company beat EPS estimates significantly ($3.17 vs $2.8 consensus) and increased its quarterly dividend, signaling confidence in operational performance.
Eli Lilly
pharmaEli Lilly is aggressively expanding US manufacturing capacity with $21B+ invested in Indiana since 2020, including a new dedicated genetic medicine facility in Lebanon. The company's blockbuster weight-loss drugs (Mounjaro, Zepbound) and tirzepatide pipeline are driving strong financial performance and bullish analyst sentiment.
Pfizer
pharmaPfizer beat Q1 2026 earnings expectations with $14.5B in revenue, driven by strong performance from launched and acquired drugs, though adjusted EPS declined 18% year-over-year. The company faces a significant $17B patent cliff from key drug expirations like Eliquis and Vyndaqel, requiring successful pipeline launches and acquired product integration to sustain growth.